Pα+ Psychedelic Bulletin #198: New Data Offers Look at Spravato’s Long-Term Use, Highlights Psychedelic Opportunity; MAHA Report Slams Psychiatric Meds; Momentum Builds for Beckley
- New Data Offers Look at Spravato’s Long-Term Use, Highlights Opportunity for Psychedelics
- MAHA Report Slams Psychiatric Drug Use Among America’s Youth
- Beckley’s Small Study Supports Adjunctive Use of 5-MeO-DMT with SSRIs in TRD
- Other Stories
New Data Offers Look at Spravato’s Long-Term Use, Highlights Opportunity for Psychedelics
Earlier this month, a manuscript by Zaki et al. (2025) looked at the long-term safety and efficacy of esketamine nasal spray (Spravato) in treatment-resistant depression (TRD). It provides an unprecedented look at how the product is used over the medium and long term, such as average treatment duration, reasons for discontinuation, and outcomes.
The data is derived from the open-label long-term extension study conducted by the drug’s manufacturer, Janssen (part of Johnson & Johnson), between June 2016 and December 2022 (SUSTAIN-3). It represents 1,148 patients who participated in the company’s Phase 3 studies of the drug, who were exposed to Spravato for a cumulative 3,777 patient-years.
Headline findings include a mean exposure to Spravato of 42.9 months, i.e. just over three and a half years. That is substantial, especially given the context of in-person clinic visits and the fact that much of the long-term extension study took place during the peak of the COVID-19 pandemic...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks